Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Antipsychotic drug risperidone reduces tics in children and adults with tourette syndrome

Yale University : 17 April, 2003  (New Product)
A study by Yale researchers suggests that the atypical antipsychotic drug risperidone reduces tic symptoms in children and adults with Tourette syndrome.
'These results suggest that risperidone is safe and effective for short-term treatment of tics in children or adults with Tourette syndrome,' said lead author Lawrence Scahill, associate professor in the Yale School of Nursing and the Yale Child Study Center. 'Longer-term studies are needed to evaluate the durability of efficacy and safety over time.'

Published in the current issue of Neurology, the study looked at 34 patients (26 children and eight adults) who were randomly assigned to receive either risperidone or a placebo for eight weeks. The medication or a placebo was administered on a gradually increasing dose to minimize side effects over the first four weeks of the study. Patients were seen every other week to evaluate response and adjust the dose. The primary outcome measure was based on patient and family interviews by a clinician who was blind to the treatment assignment.

After eight weeks of treatment, the 16 subjects on risperidone showed a 32 percent reduction in tic severity. The placebo group showed only a seven percent reduction. Scahill said this difference was statistically and clinically significant. Similar results were observed when the children were evaluated separately. The 12 children randomized to risperidone showed a 36 percent reduction in tic symptoms compared to an 11 percent decrease in the 14 children on placebo. The medication was generally well tolerated.

'Of particular note is that there were no neurological side effects such as dystonia, dyskinesia or restlessness, which are often seen in the traditional antipsychotic medications that are commonly used for the treatment of tics in TS,' said Scahill.

Symptoms of Tourette syndrome include persistent motor and phonic tics affecting one to eight per 1,000 school-age children. The tics include jerking movements of the body and involuntary vocalizations. Common motor tics include eye blinking, facial movements, head jerking or shrugging. Common vocal tics include grunting, coughing, throat clearing or snorting. In many cases the tics are mild and may not require treatment with medication. When tics occur frequently, in combinations or involve more disruptive movements or sounds, medication is prescribed. Until recently, few new medications were available for the treatment of tics.

Risperidone, which was developed for the treatment of adults with schizophrenia, was introduced in 1994. This study was the second to compare risperidone and placebo in a randomized clinical trial.

Collaborators on the study included Yale Child Study Center researchers James Leckman, Robert Schultz, Lily Katsovich and Bradley Peterson, who is now at Columbia University.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo